Rethinking care for multiple myeloma

Innovating relapsed refractory multiple myeloma care: Unmet needs, therapy management and real-world experience

How are care needs evolving in the relapsed and refractory multiple myeloma (RRMM) space? Hear expert perspectives in symposium highlight clips from the 30th European Hematology Association (EHA) Congress in Milan, Italy. María Victoria Mateos (University of Salamanca, Spain) chairs the discussion with Karthik Ramasamy (Oxford University Hospital, UK) and Elena Zamagni (University of Bologna, Italy).

Access the EMA Summary of Product Characteristics (SmPC) for selinexor. Adverse event reporting information can be found at the bottom of the page.

How are treatment decisions evolving in MM? María Victoria Mateos discusses the latest EHA-EMN guideline updates, strategies for relapsed and lenalidomide-refractory patients, and options for second-line through later lines, including approaches for daratumumab-sensitive disease. View transcript.

Could XPO1 inhibition reshape the treatment landscape in MM? María Victoria Mateos discusses the BOSTON study design, key efficacy results, outcomes in bortezomib-naive and lenalidomide-refractory patients, and the safety profile of selinexor. View transcript.

"If we use these fairly simple measures then we can improve outcomes for patients.” Karthik Ramasamy discusses strategies to manage adverse events including gastrointestinal side effects in people with MM treated with selinexor, before discussing data on the relationship between dose reduction and treatment efficacy in the BOSTON trial. View transcript.

“The subsequent relapses were very disappointing.” Elena Zamagni presents a clinical case study of a 71-year-old male with high-risk MM, detailing the treatment journey from first to eighth line, including relapses, adverse events, and dose reduction. View transcript.

What can we learn from a frail, high-risk MM case? Elena Zamagni presents the journey of a 79-year-old patient with comorbidities and double-refractory relapse, highlighting therapy choices and safety challenges. View transcript.

Meet the experts

María Victoria Mateos, MD, PhD

María Victoria Mateos is a Consultant Physician in Hematology at the University of Salamanca, Spain. She is also responsible for coordinating the clinical trials unit and is Director of the Myeloma Program. Her scientific interests include MM, the biology of plasma cells, and new drug development.

Disclosures: Honoraria received from lectures and participation in advisory boards from AbbVie, Amgen, Bristol Myers Squibb, GSK, Janssen, Kite Pharma, Menarini Stemline, Pfizer, Regeneron, Roche, and Sanofi.

Karthik Ramasamy, MBBS, FRCP, FRCPath, PhD

Karthik Ramasamy is a Consultant Hematologist at Oxford University Hospitals NHS Trust, UK. His research interests include early diagnosis of MM, bone disease, and myeloma drug resistance mechanisms.

Disclosures: Involved in advisory boards for AbbVie, Adaptive Biotechnologies, Amgen, Celgene, EUSA Pharma, GSK, Janssen, Karyopharm Therapeutics, Menarini Stemline, Pfizer, Recordati, Sanofi, and Takeda. Received honoraria from Adaptive Biotechnologies, Celgene (Bristol Myers Squibb), GSK, Janssen, Menarini Stemline, Pfizer, Recordati, Sanofi, and Takeda. Received research support from Amgen, Celgene, GSK, Johnson & Johnson, Sanofi, and Takeda.

Elena Zamagni, MD, PhD

Elena Zamagni is Associate Professor of Hematology at the University of Bologna, Italy. Her research interests center on MM, with emphasis on high-dose therapy supported by stem cells, prognostic indicators, measurable residual disease, innovative therapeutic approaches, and imaging modalities.

Disclosures: Advisory board participation and consultancy for Amgen, Bristol Myers Squibb, GSK, Janssen, Menarini Stemline, Oncopeptide, Pfizer, and Sanofi.